Select Page
  1. Home
  2.  » 
  3. Our Locations
  4.  » 
  5. Europe
  6.  » Nottingham, UK

Nottingham, UK

Catalent’s Nottingham facility focuses on early stage development of small molecule drug candidates from the bench to clinic.  This facility offers an array of services that support oral dosage forms that include characterization, formulation and analytical development, manufacturing and clinical packaging, labeling and worldwide distribution.  Our Nottingham location is the home of our bioavailability enhancement technologies, including Catalent Spray Drying and OptiMelt™ Hot Melt Extrusion to support the needs of our client’s most challenging compounds. The MHRA approved facilities include cGMP dose form manufacturing, packaging, analytical and development laboratories.

Size: 37,600 ft2

ADDRESS

8 Orchard Place
Nottingham Business Park
Nottingham NG8 6PX, UK

PHONE

+44 (0)115 871 8888

Title Address Description
Nottingham, UK Location
8 Orchard Pl, Nottingham NG8 6PX, UK

ACCREDITATIONS

  • ANVISA Approved
  • EMA Approved

SALES INQUIRIES

Reach out to one of our experts to discuss any of our offerings or a specific solution for your project challenges.

CAREERS

We recognize talent is our most important asset. To explore a career with Catalent, visit our Careers Section to submit your resume, or contact us at careers@catalent.com.

GENDER PAY GAP REPORT

Catalent UK Swindon Zydis Limited (“Catalent Zydis”) continues to be an organisation committed to the growth, development, and engagement of our people, within an inclusive culture.  As a UK based organisation of over over 250 employees, we now report our gender pay data. Please download here.

CATALENT UK RETIREMENT AND DEATH BENEFIT PLAN (“PLAN”) – CHAIR’S STATEMENT RELATING TO THE DEFINED CONTRIBUTION SECTION

The defined contribution section of the Plan (DC Section) is now closed and all members’ benefits in the DC Section have been transferred out of the Plan.

Before the DC Section closed, the chair of trustees was required to publish a statement that covered the Statement of Investment Principles (SIP) in relation to the default arrangement and the charges and transaction costs borne by members. The most recent and final chair’s statement was prepared in December 2018 and can be accessed here. Please note that this is a historic document which was prepared before the DC Section closed and is provided for information only.

CATALENT UK TAX STRATEGY

The purpose of this statement is to satisfy the UK legislative requirements of Schedule 19 Finance Act 2016 in relation to the publication of tax strategy insofar as it affects the UK companies in the Catalent group for the year ended 30 June 2019. Please download here.

*The services described on this page are supplied in the U.K. by a wholly owned subsidiary of Catalent named Juniper Pharma Services Limited, 8 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX, U.K.